Familial hypercholesterolaemia trials in Norway

5 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 12 November 2026. Ask the study team whether a trial fits you.

• Phase 2/3Taking people
  A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029)

  Where

  Oslo

  Age

  6 years to 17 years

  People

  153 worldwide

  Run by

  Merck Sharp & Dohme LLC

  See details and how to joinNCT07058077 · EU 2024-519068-42-00
• Phase 3Taking people
  Study of Zodasiran in Adolescent Participants With Homozygous Familial Hypercholesterolemia

  Where

  Oslo

  Age

  12 years to 17 years

  People

  10 worldwide

  Run by

  Arrowhead Pharmaceuticals

  See details and how to joinNCT07473843 · EU 2025-523662-24-00
• Phase 3Taking people
  Long-term Safety and Tolerability of Inclisiran in Participants With HeFH or HoFH Who Have Completed the Pediatric ORION-16, ORION-13, ORION-20, or ORION-19 Studies

  Where

  Oslo

  Age

  2 years to 100 years

  People

  195 worldwide

  Run by

  Novartis Pharmaceuticals

  See details and how to joinNCT05682378
• Phase 3Enrolling by invitation
  Study to Evaluate the Efficacy and Safety of Lerodalcibep in Children 6 to 17 Years, With Heterozygous FH

  Where

  Oslo

  Age

  6 years to 17 years

  People

  150 worldwide

  Run by

  LIB Therapeutics LLC

  See details and how to joinNCT07102511 · EU 2025-524214-28-00
• Phase 4Not yet taking people in Norway
  Reassessment of statin-associated muscle symptoms in adults with familial hypercholesterolemia

  Where

  Oslo, Trondheim

  Age

  18 years and over

  People

  70

  Run by

  Oslo University Hospital HF

  See details and how to join2025-521589-83-00 · EU 2025-521589-83-00